Evaluation of Serum Adrenal Androgens Among Prepubertal and Pubertal Boys With Autism Spectrum Disorder
- Conditions
- Autism Spectrum Disorder
- Interventions
- Diagnostic Test: serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfateDiagnostic Test: The Childhood Autism Rating Scale (CARS)Diagnostic Test: DSM-5 Diagnostic Criteria for ASD
- Registration Number
- NCT05811507
- Lead Sponsor
- Sohag University
- Brief Summary
Autism spectrum disorder (ASD) is a neurodevelopmental disorder of unclear etiology. There are theories depicting the importance of sex steroid hormones in autism, since the prevalence of the disorder is male-biased. What makes boys more vulnerable to achieve the diagnosis of autism remains unclear. One of the theories strengthens the importance of fetal organizational effect of testosterone on brain development. Baron Cohen with coworkers showed that elevated fetal levels of several androgens including testosterone were high in male-fetuses who later in postnatal life achieved the diagnosis of autism and fetal testosterone levels were positively correlated with autistic traits in general population.
Females with conditions of abnormal prenatal exposure to testosterone and its sex steroid precursors, such as congenital adrenal hyperplasia and polycystic ovary syndrome, were found to have higher rate of autistic traits as well as their children were of higher risk of developing autism. However, the exact mechanism by which these hormones influence the manifestation of autistic traits remains undiscovered. Another model explaining higher prevalence of ASD in males is a female protective model which suggests that multiple genetic factors contribute to the development of ASD and that higher threshold of genetic liability is required in females compared to males. Zhang et al. demonstrated genetic evidence of sex differences in ASD confirming female protective model, employing investigation of de novo mutations, common variants of ASD candidate genes and their co-expression in male and female brain.
During infancy: The Gonadotropin releasing hormone (GnRH) pulse generator is reactivated by 6 to 10 days after birth. This period, termed the mini puberty of infancy, was first described in the 1970s. During mini puberty, luteinizing hormone (LH) levels approximate pubertal concentrations, reaching a peak between 16 and 20 days of life. Serum testosterone levels rise in response to rising concentrations of LH, paralleling an increase in Leydig cell number and testicular testosterone concentrations. Serum testosterone levels peak from 1 to 3 months (210 ± 130 ng/dL or 7.28 ± 4.51 nmol/L on day of life 30) and decline by roughly 50% per month reaching prepubertal levels by 7 to 12 months of age. Dihydrotestosterone (DHT) concentrations parallel the rise in testosterone, reaching pubertal values during the early postnatal period.
During puberty: Testosterone is produced primarily by the testes, though a small amount is also made in the adrenal gland. Gonadarche refers to the onset of sex steroid production from the gonads and occurs in response to pulsatile production of GnRH from the hypothalamus, which in turn stimulates production of LH and Follicle stimulating hormone (FSH) from the pituitary gland. LH stimulates the Leydig cells to produce testosterone, whereas FSH stimulates the Sertoli cells to proliferate and initiate spermatogenesis.
Active androgens are synthesized via two alternative pathways. The first of them is known as the classic "frontdoor" pathway with pregnenolone serving as androgen precursor, which underwent a conversion to DHEA and subsequently to androstenediol. These metabolic steps are catalyzed by CYP17A1 (in the C17,20-lyase step) and (mostly adrenal) AKR1C3 enzyme, respectively. Dehydroepiandrosterone (DHEA) and androstenediol are readily sulfated by SULT2A1 in adrenal cortex and their sulfates serve as the stock pool for the production of active androgens of the adrenal origin as the production of androgens in early childhood of boys is limited to extra-gonadal tissues, such as adrenal, skin, etc. These sulfated primary androgens may be subsequently deconjugated and metabolized by HSD3B1 and HSD3B2 isoforms to androstenedione and Total testosterone (TST) and then to 5α/β-reduced 17-oxo- and 17β-androgens, respectively. In addition, the androstenedione may be readily converted to testosterone by adrenal AKR1C3. From the aforementioned substances, TST, 5α-dihydrotestosterone, and 11-oxo-testosterone are known as the most potent bioactive androgens. Besides the "frontdoor" pathway the dihydrotestosterone may be also formed by so called "backdoor" pathway. This pathway is based on a direct conversion of 5α/β-reduced pregnane steroids (C21) to their 5α/β-reduced androgen (C19) metabolites which is catalyzed by the same enzyme converting pregnenolone to DHEA (CYP17A1 in the C17,20-lyase step). These 5α/β-reduced androgen (C19) metabolites include also the most active androgen 5α-dihydrotestosterone. The "backdoor" pathway is crucial for androgen synthesis in marsupials but may also be active in various human steroid-related disorders.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- Male
- Target Recruitment
- 100
- Age: 6-18 years
- Proved diagnosis by clinical manifestations of ASD in addition to DSM-V Criteria
- Assessment of ASD severity by Childhood Autism Rating Scale (CARS)
- Those with history of metabolic and neurodegenerative disease
- Medication History: Those on long-term use of antibiotics, non-steroidal drugs, immune-stimulants or immune-suppressive drugs
- Those with structural brain abnormalities
- Those with audiological or visual problems
- Those with other psychiatric problems
- Those with history of systemic illness as allergic disease, immunodeficiency or autoimmune disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cases group of patients: The Childhood Autism Rating Scale (CARS) It will include patients with autism spectrum disorder.. Cases group of patients: serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate It will include patients with autism spectrum disorder.. control group of patients: serum total testosterone, serum androsterone, serum androstenedione and serum dehydroepiandrosterone sulfate It will include healthy boys who don't have any manifestations of ASD according to DSM-V Criteria and CARS score, and are age and Tanner stage matched to cases. control group of patients: The Childhood Autism Rating Scale (CARS) It will include healthy boys who don't have any manifestations of ASD according to DSM-V Criteria and CARS score, and are age and Tanner stage matched to cases. control group of patients: DSM-5 Diagnostic Criteria for ASD It will include healthy boys who don't have any manifestations of ASD according to DSM-V Criteria and CARS score, and are age and Tanner stage matched to cases. Cases group of patients: DSM-5 Diagnostic Criteria for ASD It will include patients with autism spectrum disorder..
- Primary Outcome Measures
Name Time Method serum dehydroepiandrosterone sulfate (DHEAS) level baseline serum dehydroepiandrosterone sulfate (DHEAS) will be measured in (mcgldl)
serum androstenedione level baseline serum androstenedione level will be measured in (nglml)
Assessment of severity of autism baseline Assessment of severity of autism by Childhood Autism Rating Scale (CARS)
serum androsterone level baseline serum androsterone level will be measured in (nglml)
serum total testosterone level. baseline serum total testosterone level will be measured in (nglml).
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Sohag University Hospital
🇪🇬Sohag, Egypt